Nano-technology for targeted drug delivery to combat antibiotic resistance

Expert Opinion on Drug Delivery

Volumn 9, Issue 11, 2012, Pages 1325-1332

  Sharma, Abhinay ^a   Kumar Arya, Deepak ^a   Dua, Meenakshi ^a   Chhatwal, Gursharan Singh ^b   Johri, Atul Kumar ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Alternative antimicrobials; Antibiotic resistance; Nano technology; Targeted drug delivery

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; BIOPOLYMER; CARBAPENEM DERIVATIVE; CARBON NANOTUBE; CEPHALOSPORIN DERIVATIVE; CHITOSAN; CHOLESTEROL; COPPER NANOPARTICLE; DENDRIMER; DIPALMITOYLPHOSPHATIDYLCHOLINE; LIPOSOME; MONOBACTAM DERIVATIVE; NANOCAPSULE; NANOMATERIAL; NANOSPHERE; PHOSPHATIDYLCHOLINE; POLYGLACTIN; POLYLACTIC ACID; POLYMYXIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN SYNTHESIS INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SILVER NANOPARTICLE; SOLID LIPID NANOPARTICLE; TAUROCHOLIC ACID; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM; DRUG DELIVERY SYSTEM; DRUG TARGETING; FUNGUS; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; SEMICONDUCTOR; VIRUS CAPSID;

ANTI-BACTERIAL AGENTS; DEVELOPING COUNTRIES; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MICROBIAL; HUMANS; NANOTECHNOLOGY;

EID: 84867838456     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.717927     Document Type: Article

References (74)

1. Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Resist Updat 2011;14:118-24
2. Bush K, Courvalin P, Dantas G, et al. Tackling antibiotic resistance. Nat Rev Microbiol 2011;9:894-6
3. Bassetti M, Ginocchio F, Mikulska M, et al. Will new antimicrobials overcome resistance among Gram-negatives? Expert Rev Anti Infect Ther 2011;9:909-22
4. Koomanachai P, Crandon JL, Nicolau DP. Newer developments in the treatment of Gram-positive infections. Expert Opin Pharmacother 2009;10:2829-43
5. van Hal SJ, Paterson DL. New Gram-positive antibiotics: better than vancomycin? Curr Opin Infect Dis 2011;24:515-20
6. Blecher K, Nasir A, Friedman A. The growing role of nanotechnology in combating infectious disease. Virulence 2011;2:395-401
7. Veerapandian M, Yun K. Functionalization of biomolecules on nanoparticles: specialized for antibacterial applications. Appl Microbiol Biotechnol 2011;90:1655-67
8. Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009;17:2950-62
9. Gaucher G, Marchessault RH, Leroux JC. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J Control Release 2010;143:2-12
10. Subbiah R, Veerapandian M, Yun KS. Nanoparticles: functionalization and multifunctional applications in biomedical sciences. Curr Med Chem 2010;17:4559-77
11. Allahverdiyev AM, Kon KV, Abamor ES, et al. Coping with antibiotic resistance: combining nanoparticles with antibiotics and other antimicrobial agents. Expert Rev Anti Infect Ther 2011;9:1035-52
12. Banerjee M, Mallick S, Paul A, et al. Heightened reactive oxygen species generation in the antimicrobial activity of a three component iodinated chitosan-silver nanoparticle composite. Langmuir 2010;26:5901-8
13. Ma Y, Zhou T, Zhao C. Preparation of chitosan-nylon-6 blended membranes containing silver ions as antibacterial materials. Carbohydr Res 2008;343:230-7
14. Sanpui P, Murugadoss A, Prasad PV, et al. The antibacterial properties of a novel chitosan-Ag-nanoparticle composite. Int J Food Microbiol 2008;124:142-6
15. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev 2010;62:394-407
16. Friedman AJ, Han G, Navati MS, et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide 2008;19:12-20
17. Potara M, Jakab E, Damert A, et al. Synergistic antibacterial activity of chitosan-silver nanocomposites on Staphylococcus aureus. Nanotechnology 2011;22:135101
18. Ulrich AS. Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep 2002;22:129-50 (Pubitemid 35222729)
19. Drulis-Kawa Z, Dorotkiewicz-Jach A. Liposomes as delivery systems for antibiotics. Int J Pharm 2010;387:187-98
20. Allen TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 1998;56:747-56 (Pubitemid 28525935)
21. Bakker-Woudenberg IA, Lokerse AF, ten Kate MT, et al. Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. J Infect Dis 1993;168:164-71 (Pubitemid 23178744)
22. Bakker-Woudenberg IA, Storm G, Woodle MC. Liposomes in the treatment of infections. J Drug Target 1994;2:363-71
23. Bakker-Woudenberg IA. Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci. Int J Antimicrob Agents 2002;19:299-311 (Pubitemid 34308978)
24. Pal S, Tak YK, Song JM. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium Escherichia coli. Appl Environ Microbiol 2007;73:1712-20 (Pubitemid 46449051)
25. Ghosh S, Kaushik R, Nagalakshmi K, et al. Antimicrobial activity of highly stable silver nanoparticles embedded in agar-agar matrix as a thin film. Carbohydr Res 2010;345:2220-7
26. Shahverdi AR, Fakhimi A, Shahverdi HR, et al. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli. Nanomedicine 2007;3:168-71 (Pubitemid 46899614)
27. Ruparelia JP, Chatterjee AK, Duttagupta SP, et al. Strain specificity in antimicrobial activity of silver and copper nanoparticles. Acta Biomater 2008;4:707-16 (Pubitemid 351461288)
28. Martinez-Gutierrez F, Olive PL, Banuelos A, et al. Synthesis, characterization, and evaluation of antimicrobial and cytotoxic effect of silver and titanium nanoparticles. Nanomedicine 2010;6:681-8
29. Ren G, Hu D, Cheng EW, et al. Characterisation of copper oxide nanoparticles for antimicrobial applications. Int J Antimicrob Agents 2009;33:587-90
30. Prajapati VK, Awasthi K, Yadav TP, et al. An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis. J Infect Dis 2012;205:333-6
31. Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res 2008;41:60-8
32. Pantarotto D, Briand JP, Prato M, et al. Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem Commun (Camb) 2004;1:16-17 (Pubitemid 38121939)
33. Georgakilas V, Kordatos K, Prato M, et al. Organic functionalization of carbon nanotubes. J Am Chem Soc 2002;124:760-1 (Pubitemid 34112779)
34. Soppimath KS, Aminabhavi TM, Kulkarni AR, et al. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1-20 (Pubitemid 32144788)
35. Zhang L, Pornpattananangku D, Hu CM, et al. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem 2010;17:585-94
36. Santos-Magalhaes NS, Mosqueira VC. Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev 2010;62:560-75
37. Sosnik A, Carcaboso AM, Glisoni RJ, et al. New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev 2010;62:547-59
38. Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Des 2006;12:4669-84 (Pubitemid 44835136)
39. Huh AJ, Kwon YJ. "Nanoantibiotics": A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release 2011;156:128-45
40. Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005;10:35-43 (Pubitemid 40164817)
41. Cheng Y, Qu H, Ma M, et al. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: An in vitro study. Eur J Med Chem 2007;42:1032-8 (Pubitemid 46907335)
42. Vaks L, Benhar I. In vivo characteristics of targeted drug-carrying filamentous bacteriophage nanomedicines. J Nanobiotechnol 2011;9:58
43. Jung J, Matsuzaki T, Tatematsu K, et al. Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials. J Control Release 2008;126:255-64
44. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011;63:136-51
45. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011;24:71-109
46. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: A new paradigm for antimicrobial therapy. Nat Chem Biol 2007;3:541-8 (Pubitemid 47294400)
47. Arnusch CJ, Albada HB, van Vaardegem M, et al. Trivalent ultrashort lipopeptides are potent pH dependent antifungal agents. J Med Chem 2012;55:1296-302
48. Fjell CD, Hiss JA, Hancock REW, et al. Designing antimicrobial peptides: form follows function. Nature Rev drug Disc 2012;11:37-51
49. Manca ML, Manconi M, Valenti D, et al. Liposomes coated with chitosan-xanthan gum (chitosomes) as potential carriers for pulmonary delivery of rifampicin. J Pharm Sci 2012;101:566-75
50. Alexander BD, Winkler TP, Shi S, et al. In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols. Pharm Dev Technol 2011;16:577-82
51. Fielding RM, Lewis RO, Moon-McDermott L. Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome). Pharm Res 1998;15:1775-81 (Pubitemid 28524591)
52. Magallanes M, Dijkstra J, Fierer J. Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis. Antimicrob Agents Chemother 1993;37:2293-7 (Pubitemid 23324446)
53. Omri A, Suntres ZE, Shek PN. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem Pharmacol 2002;64:1407-13 (Pubitemid 35248257)
54. Onyeji CO, Nightingale CH, Marangos MN. Enhanced killing of methicillin-resistant Staphylococcus aureus in human macrophages by liposome-entrapped vancomycin and teicoplanin. Infection 1994;22:338-42 (Pubitemid 24316420)
55. Kim HJ, Jones MN. The delivery of benzyl penicillin to Staphylococcus aureus biofilms by use of liposomes. J Liposome Res 2004;14:123-39 (Pubitemid 40052466)
56. Schumacher I, Margalit R. Liposome-encapsulated ampicillin: Physicochemical and antibacterial properties. J Pharm Sci 1997; 86:635-41 (Pubitemid 27203415)
57. Gangadharam PR, Ashtekar DA, Ghori N, et al. Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice. J Antimicrob Chemother 1991;28:425-35
58. Cavalli R, Gasco MR, Chetoni P, et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002;238:241-5 (Pubitemid 34457892)
59. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005;85:227-34 (Pubitemid 40805619)
60. Sanna V, Gavini E, Cossu M, et al. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies. J Pharm Pharmacol 2007;59:1057-64 (Pubitemid 47265352)
61. Jain D, Banerjee R. Comparison of ciprofloxacin hydrochloride-loaded protein, lipid, and chitosan nanoparticles for drug delivery. J Biomed Mater Res B Appl Biomater 2008;86:105-12 (Pubitemid 351874373)
62. Tsiolis P, Giamarellos-Bourboulis EJ, Mavrogenis AF, et al. Experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus treated with a polylactide carrier releasing linezolid. Surg Infect (Larchmt) 2011;12:131-5
63. Espuelas MS, Legrand P, Loiseau PM, et al. In vitro antileishmanial activity of amphotericin B loaded in poly (epsilon-caprolactone) nanospheres. J Drug Target 2002;10:593-9 (Pubitemid 36124359)
64. Toti US, Guru BR, Hali M, et al. Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials 2011;32:6606-13
65. Ungaro F, d'Angelo I, Coletta C, et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release 2012;157:149-59
66. Valizadeh H, Mohammadi G, Ehyaei R, et al. Antibacterial activity of clarithromycin loaded PLGA nanoparticles. Pharmazie 2012;67:63-8
67. Forestier F, Gerrier P, Chaumard C, et al. Effect of nanoparticle-bound ampicillin on the survival of Listeria monocytogenes in mouse peritoneal macrophages. J Antimicrob Chemother 1992;30:173-9
68. Turos E, Shim JY, Wang Y, et al. Antibiotic-conjugated polyacrylate nanoparticles: new opportunities for development of anti-MRSA agents. Bioorg Med Chem Lett 2007;17:53-6 (Pubitemid 46001585)
69. Turos E, Reddy GS, Greenhalgh K, et al. Penicillin-bound polyacrylate nanoparticles: restoring the activity of beta-lactam antibiotics against MRSA. Bioorg Med Chem Lett 2007;17:3468-72 (Pubitemid 46830890)
70. Abeylath SC, Turos E, Dickey S, et al. Glyconanobiotics: Novel carbohydrated nanoparticle antibiotics for MRSA and Bacillus anthracis. Bioorg Med Chem 2008;16:2412-18 (Pubitemid 351403660)
71. Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2007;2:16
72. Ma M, Cheng Y, Xu Z, et al. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug. Eur J Med Chem 2007;42:93-8 (Pubitemid 46198989)
73. Mishra MK, Kotta K, Hali M, et al. PAMAM dendrimer-azithromycin conjugate nanodevices for the treatment of Chlamydia trachomatis infections. Nanomedicine 2011;7:935-44
74. Bhadra D, Bhadra S, Jain NK. Pegylated lysine based copolymeric dendritic micelles for solubilization and delivery of artemether. J Pharm Pharm Sci 2005;8:467-82 (Pubitemid 41529323)